Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI chatbot help autism caregivers find their way?

NCT ID NCT07821619

Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing an AI-enabled support tool for parents and caregivers of children with autism in Indiana and western Kenya. The tool offers plain-language autism information, answers caregiver questions, supports coping, and helps families find local services, with safety guardrails for high-risk concerns. About 60 caregivers will use the tool and complete surveys to see whether it is practical, acceptable, safe, and engaging. The study aims to prepare for a larger trial that would measure whether the tool improves caregiver knowledge, confidence, and service access.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI-enabled autism caregiver support tool
What this could lead to
If the tool proves feasible and safe, it could shape a larger trial testing whether AI support improves caregiver knowledge, confidence, and access to services.
What could go wrong
This is a small pilot with 60 caregivers, so it cannot show whether the tool improves outcomes. AI tools can give wrong or unsafe advice, and the study mainly checks whether the approach is practical and acceptable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2028

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult caregiver aged 18 years or older. * Parent or primary caregiver of a child with autism spectrum disorder. * Resides within the study catchment area in Indiana, United States or western Kenya. * Able to provide informed consent. * Has access to a mobile phone, tablet, or computer capable of accessing the AI-enabled caregiver support tool. * Able to communicate in a study-supported language. * Willing to use the AI-enabled caregiver support tool and complete study assessments. Exclusion Criteria: * Younger than 18 years of age. * Unable or unwilling to provide informed consent. * Unable to access the AI-enabled caregiver support tool using an internet-connected device. * Unable to complete study procedures or assessments due to cognitive, communication, or other limitations that preclude participation. * Currently participating in another study that, in the opinion of the investigators, would interfere with study participation or interpretation of study findings.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autism spectrum disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Moi Teaching and Referral Hospital

    Eldoret, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.